Sanofi-Aventis Antibiotic Under Scrutiny
14th Nov 2006, 22:08 GMT
A Sanofi-Aventis antibiotic linked to rare reports of severe liver problems -- including several deaths -- will be subjected to new scrutiny by the FDA.
Sanofi-Aventis Antibiotic Under Scrutiny related news:
- In wake of deaths, FDA subjects antibiotic to new scrutiny — USATODAY.com Health - Top Stories
- FDA subjects antibiotic to new scrutiny (Associated Press) — Yahoo! Health: Health News
- FDA Subjects Antibiotic to New Scrutiny — AP Top Health News At 10:37 a.m.
- FDA subjects antibiotic to new scrutiny (AP) — Yahoo! News: Health News
- FDA subjects antibiotic to new scrutiny in wake of reports of death and injury — WOODTV - Political News
- Volume 194, number 12: Antibiotic Selection May Contribute to Increases in Macrolide-Resistant Treponema pallidum — J Infect Dis Latest Issue
- Optimer Files for IPO to Fund Antibiotic Tests — RedOrbit News - Health
- They skipped the light fandango and are turning cartwheels in the courts — TimesOnline: Britain
- The National Awards are illegal! — The Times Of India - Ahmedabad Times
- English Al-Jazeera expects 'scrutiny' — USATODAY.com Life - Media Mix
Latest news from WSJ.com: US Business:
- Merck's Arcoxia Draws Mixed Reviews
- Benetton Top Executives Resign
- Apple Names Rosenberg General Counsel
- Gutierrez Aims to Help U.S. Business in China
- Tyson Swings to Loss as Demand Wanes
- Eddie Bauer Agrees to Be Acquired
- Web Companies Seek Review of Fees
- Delta Cuts Bargain Fares
- Illumina to Buy Solexa for $600 Million
- BlackJack Is BlackBerry's Newest Rival